Aclarion Inc ACON

$1.56 -0.03 (-1.89%)

Valuation

Market cap
4,583,000
Revenue TTM
$80,000
Net income TTM
$-7,230,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-9,037.50%
Debt to equity
0.00

Trading

Volume
10,600
Avg volume
30,414
Day's range
$1.56 – $1.63
Shares out
2,882,000
Stochastic %K
8%
Beta
1.21
Analysts
Moderate Buy
Price target
$7.50

Price

Company profile

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software...

Show more

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Industry
Health Information Services
Sector
Healthcare
Phone
833 275 2266
Website
https://www.aclarion.com
Address
8181 Arista Place, Suite 100, Broomfield, United States

Latest news

No headlines yet.

Stocktwits

gapureau Nov 13, 1:12 AM
$ACON Brett Ness, the CEO and Jeff Thramann, Executive Director "both" have $300,000 Annual Base Salary and "both" also received a $162,500 Bonus for 2025. So just how long would "You" try to stretch out such a Gravy Train. They have already been doing it for many years with no end in sight.
0 replies
Apes_Strong Nov 9, 1:49 AM
$ACON ask yourself this, why did they not take the $4 buyout ?
1 replies
Apes_Strong Nov 9, 1:49 AM
$ACON they have no interest in the well being of the shareholders Ness and Tharmann are criminal coconspirators They are management of nothing. This is a scam to collect hundreds of thousands of dollars per year in salaries and milk the balance sheet dry indefinitely
0 replies
Huskersnsaints Nov 5, 7:11 PM
$ACON What a shame 9200 shares drop this 10%, The stock that only goes down not matter how light the volume, IF THIS MGT WAS CONFIDENT IN THIS COMPANY THEY WOULD BUY BSCK SHARES OR SOMETHING, ALL THESE pr's mean nothing with no revenue!!!! Just good Pr's and hope!!!!
1 replies
Putnik Nov 2, 11:28 PM
$ACON come on start buying back again get this shit to 2.50 and drop trial news fuckers!
0 replies
Apes_Strong Nov 2, 10:26 PM
$ACON Ness and Tharmann are criminal coconspirators along with their criminal pump and dump banker, Bobby Dawson
0 replies
Apes_Strong Nov 2, 10:25 PM
$ACON the consequences of criminal management Once they are taken out in handcuffs, shareholder value may be repaired
0 replies
Mar_3 Oct 30, 7:51 PM
$ACON Company does great things but what a shit stock. $14 million in cash, declined a $4 per share buyout, and CLARITY keeps expanding sites. Yet we continue to decline. Hope for better ahead but man this sucks
1 replies